Sector tariff now more than a threat – for some Rx companies
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on bioworld.com
Leave the platform to read the original full article on the publisher site.
Source: BioWorld Regulatory RSS
Scope: Regulatory
Related coverage
More related coverage
Pharmac invites feedback before possible medicine brand changes
What's New Related to Drugs
Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety...
Epinephrine Auto-Injector Devices by Amneal and Impax: CDER Alert - FDA Alerts Patients and Health Care Professionals About Device Malfunction
FDA is alerting the public to immediately inspect certain lots of Amneal and Impax epinephrine auto-...
What’s New for Biologics
Latest news from the Center for Biologics Evaluation and Research